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Abstract
Background: Diagnosis of tuberculous (TB) pleuritis is difficult and better diagnostic tools are needed.
New blood based interferon-gamma (IFN-γ) tests are promising, but sensitivity could be low in HIV
positive patients. The IFN-γ tests have not yet been validated for use in pleural fluid, a compartment with
higher level of immune activation than in blood.
Methods: The QuantiFERON TB®-Gold (QFT-TB) test was analysed in blood and pleural fluid from 34
patients presenting with clinically suspected pleural TB. Clinical data, HIV status and CD4 cell counts were
recorded. Adenosine deaminase activity (ADA) analysis and TB culture were performed on pleural fluid.
Results: The patients were categorised as 'confirmed TB' (n = 12), 'probable TB' (n = 16) and 'non-TB'
pleuritis (n = 6) based on TB culture results and clinical and biochemical criteria. The majority of the TB
patients were HIV infected (82%). The QFT-TB in pleural fluid was positive in 27% and 56% of the
'confirmed TB' and 'probable TB' cases, respectively, whereas the corresponding sensitivities in blood
were 58% and 83%. Indeterminate results in blood (25%) were caused by low phytohemagglutinin (PHA =
positive control) IFN-γ responses, significantly lower in the TB patients as compared to the 'non-TB' cases
(p = 0.02). Blood PHA responses correlated with CD4 cell count (r = 0.600, p = 0.028). In contrast, in
pleural fluid indeterminate results (52%) were caused by high Nil (negative control) IFN-γ responses in
both TB groups. Still, the Nil IFN-γ responses were lower than the TB antigen responses (p < 0.01),
offering a conclusive test for half of the patients. We did not find any correlation between blood CD4 cell
count and IFN-γ responses in pleural fluid.
Conclusion: The QFT-TB test in blood could contribute to the diagnosis of TB pleuritis in the HIV
positive population. Still, the number of inconclusive results is too high to recommend the commercial
QFT-TB test for routine use in pleural fluid in a TB/HIV endemic resource-limited setting.
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Tuberculosis (TB) is globally a major health burden and
human immunodefiency virus (HIV) infection is a strong
risk factor for the progression from latent infection to
active TB. In South Africa 60% of the adult TB cases are
HIV positive [1]. TB pleuritis occurs in about 30% of TB
patients, the majority of cases in the HIV positive popula-
tion [2].
The diagnosis of TB pleuritis is generally difficult and the
acid fast bacilli [AFB] microscopy method rarely detects
the tubercle bacilli, whereas culture is positive in about
40% of cases [3]. Histology of pleural biopsies could offer
a sensitivity of up to 80% in immunocompetent patients
[4], but expected to be much lower in HIV patients and
specificity is generally low [5].
Adenosine deaminase activity (ADA) in pleural fluid is
used as a marker of TB pleuritis and a meta-analysis con-
clude that although it has variable performance, it is still
a useful test [6]. However, emphyema, rheumatoid pleu-
risy and malignancy may give false positive results [7],
while immune suppression could give a false negative test
[8]. Finally, a sensitivity as low as 17% in pleural fluid has
been reported for the polymerase chain reaction (PCR)
method [9].
HIV infection has changed the nature of the clinical pres-
entation of pleural TB [2]. Patients co-infected with HIV
and TB have stronger pleural reactions than HIV negative
persons [10]. Further, T cells from the pleural cavity in
patients with TB pleuritis are more activated than those
from the peripheral blood and there seems to be a com-
partmentalisation of TB specific interferon-gamma (IFN-
γ) producing cells in the lungs of patients with active TB
[11]. T cell responses to TB antigens reside predominantly
in the CD4+ T cell subset [12]. A decline in the number of
CD4+ T cells and an expansion of activated memory
CD8+ T cells characterise chronic HIV infection [13].
Thus, it is of importance to study the immune responses
at the local site of infection in order to improve the under-
standing of the immunological mechanisms involved in
containment and progression of TB in HIV infected
patients.
TB proteins encoded by the RD-1 gene of Mycobacterium
tuberculosis (M. tuberculosis) are used in commercially
available IGRA (Interferon-gamma Release Assays) blood
tests [QuantiFERON®-TB Gold In-tube, (QFT-TB) and T
spot-TB®] [14-17]. They offer comparable high sensitivi-
ties and specificities in the diagnosis of TB in immuno-
competent patients, but there is concern about the
sensitivity in immunocompromised patients, especially
when using the QFT-TB test [18-20]. Thus, IFN-γ based
assays may give false negative TB diagnosis in endemic
areas with high burden of HIV co-infection where reliable
diagnostic tools are needed the most. Several studies have
evaluated the new IFN-γ assays in blood from patients
with active, including extrapulmonary TB, but few HIV
patients or cases of pleural TB have been included and
analyses have predominately been performed on blood
specimens [16,19,21-24].
The ELISA technique used in the QFT-TB assay could eas-
ily be adapted to routine practice and a recent review by
Gopi et al requests studies of the potential efficacy of IFN-
γ assays in the diagnosis of pleural TB [25]. In this study
we have quantified TB specific and unspecific immune
responses in the pleural cavity of patients with HIV and TB
co-infection by using the commercial available QFT-TB
test. Further, we have evaluated the utility of this test as a




Patients presenting with pleural effusion and clinical
symptoms of TB pleuritis admitted to the Dr. George
Mukhari Hospital (DGM), Ga-Rankuwa, Pretoria, South
Africa in the period 2004–2005 were recruited into the
study.
The patients were categorised as; (i) 'confirmed TB' pleu-
ritis (AFB microscopy or culture positive pleural fluid),
(ii) 'probable TB' pleuritis (AFB microscopy and culture
negative pleural fluid, ADA ≥30 U/L and/or strong clinical
evidence consistent with active TB followed by a decision
by a clinician to treat with tuberculosis chemotherapy
[26]) and (iii) 'non-TB' pleuritis when diagnosed as
malignancy or another non-TB condition. Patients with
recent TB therapy (< 1 year) or treated with corticoster-
oids, immunosuppressive or antiretroviral therapy (ART)
were not included. HIV testing was done routinely at the
hospital in pleural effusion patients with suspected TB.
The demographic and clinical data, HIV status and CD4
cell count were recorded for each patient.
Thoracocentesis and pleural biopsies (for only two
patients) were obtained according to clinical practice at
the hospital. Peripheral blood was obtained in parallel
and before initiation of anti-tuberculosis therapy. The
QFT-TB results were not available for the clinicians and
did not influence the classification of patients or decisions
concerning treatment.
The study was evaluated and approved by the Research,
Ethics and Publications Committee at the DGM Hospital,
University of Limpopo, South Africa (2003) and the
Regional Committee for Ethics in Medical Research in
Bergen, Norway (2003, REK Vest nr.185.02). All thePage 2 of 8
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study and all gave informed consent.
Specimen preparation and culture
The pleural fluid and sputum specimens were processed
according to standard laboratory routines for AFB staining
of smears and culture for up to four weeks (BacT-alert,
Organon, Teknika). The pleural fluid was also sent for
cytological examination and analysis of ADA, using a
commercial colorimetric assay kit (Diazyme General
Atomics, CA) with a cutoff value for positive test of 30 U/
L [27]. Pleural fluid mononuclear cells (PFMCs) were iso-
lated from approximately 200 ml pleural fluid by density
gradient centrifugation (Ficoll histopaque 1077, Sigma),
washed and resuspended in RPMI media (1640, L-
glutamine and HEPES supl., Sigma) to make a final con-
centration of 1 × 106 cells/ml.
QuantiFERON® TB Gold In-Tube assay
One ml of blood and 1 ml of PFMC suspension were
added to each of the three 'QuantiFERON®-TB Gold (QFT-
TB) In-tubes'; TB antigen (ESAT-6, CFP-10 and TB 7.7),
positive mitogen control (phytohemagglutinin [PHA])
and negative control (Nil), as provided by the manufac-
turer (Cellestis Ltd., Victoria, Australia), mixed well and
incubated at 37°C for 20 hours. The tubes were centri-
fuged and 500 μl of the supernatants were harvested and
stored at -70°C. until the IFN-γ was measured in dupli-
cates simultaneously in an ELISA reader. The IFN-γ con-
centrations (IU/ml) were calculated by the 'QFT-TB
analysis Software'. When the value was >15 IU/ml, the
maximum concentration that can be estimated from the
standard curve, the value was set to 15 IU/ml. For blood,
the QFT-TB test was interpreted according to instructions
by the manufacturer. The test was positive if the TB anti-
gen minus Nil value was ≥0.35 IU/ml. The Nil control had
to be ≤8 IU/ml and PHA (positive control) minus Nil had
to be ≥0.5 IU/ml or TB antigen minus Nil value had to be
≥0.35 IU/ml and ≥ 25% of the Nil for the subject to have
a valid QFT-TB test. For pleural fluid, the QFT-TB test was
interpreted as for blood, but except any upper cutoff value
for Nil. The pleural fluid supernatants were tested in 1:1,
1:10 and 1:20 dilutions. The mean IU/ml from two paral-
lel samples from the dilution that was within the range of
the assay was used to calculate the final results. The values
for the pleural fluid were then multiplied with the dilu-
tion factor in order to standardise the final results to the
number of cells (IU/1 × 106cells).
Statistics
The statistical analysis was performed by SPSS 14 (SPSS
Inc., Chicago, Il, USA). IFN-γ responses are shown as
median and ranges. The results were analysed by exact
Mann-Whitney U and Kruskal-Wallis tests (including post
hoc Mann-Whitney tests with Bonferroni correction for a
group of three post hoc comparisons) for comparison
between the TB groups. IFN-γ responses within a TB group
were analysed by exact paired sample Wilcoxon tests. The
Spearman correlation coefficient was computed for asso-
ciations between continuous variables. The relationships
between IFN-γ responses and HIV and TB status were
investigated by linear regression. A p-value of < 0.05 was
considered to indicate a statistically significant difference.
Results
Clinical and laboratory characteristics
Thirty-four patients with clinically suspected pleural TB
were enrolled in the study and the clinical and laboratory
characteristics are shown in Table 1. Chest pain, night
sweat and loss of weight were the most common clinical
symptoms seen in 85–100% of the patients.
Twelve (35%) of the patients had culture 'confirmed TB'
pleuritis, whereas 16 patients (47%) were diagnosed as
'probable TB' pleuritis based on ADA ≥30 U/L and/or clin-
ical symptoms (Table 1). Tuberculosis chemotherapy was
started in patients with clinical evidence consistent with
active TB, but response to therapy could not be recorded
since the patients were referred to outlying hospitals and
lost to follow-up. Of the remaining six patients classified
as 'non-TB' pleuritis, five were diagnosed with malignancy
by cytology and/or histology, whereas one patient did not
have a final diagnosis.





Age: median (range) 39 (20–70)
Clinical symptoms: n (%)
Chest pain 34 (100%)
Productive cough 10 (29%)
Fever 16 (47%)
Shortness of breath 16 (47%)
Night sweat 29 (85%)
Loss of weight 31 (91%)
Lymphadenopathy 27 (79%)
Oral thrush 25 (74%)
Chest x-ray infiltrates: n (%) 2 (6%)
Culture positive TB: n (%) 12 (35%)
Total TB cases: n (%) 28 (82%)
Non-TB cases: n (%) 6 (18%)
HIV positive patients: n (%) 25 (74%)
CD4 cell count HIV positive: median (range)a) 80 (7–328)
CD4 cell count > 200 cells/microL 2 (8%)
CD4 cell count 100–200 cells/microL 7 (28%)
CD4 cell count < 100 cells/microL 13 (52%)
CD4 cell count HIV negative: median (range) 457 (241–927)
a) CD4 cell count was not available for three of the patients.Page 3 of 8
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tive. The median CD4 cell count was 77 cells/microL
(range 7–280) and 162 cells/microL (range 7–548) for the
'confirmed TB' and 'probable TB' patients, respectively (p
> 0.05). The 'non-TB' group (two HIV positive and four
HIV negative) had a median CD4 cell count of 302 cells/
microL (100–927), higher than the 'confirmed TB' group
(p = 0.01), but not statistically different from the 'proba-
ble TB' group (p > 0.05). However, when adjusted for HIV
status there was no significant difference in CD4 cell
count between any of the groups.
All 'confirmed TB' patients had ADA values above 30 U/L,
whereas this was the case for 15/16 of the 'probable TB'
patients. The ADA concentrations were comparable in the
'confirmed TB' and 'probable TB' groups [68 U/L (range
38–133) and 60 U/L (range 29–200), respectively] but as
expected significantly higher than in the 'non-TB' group
[14 U/L (range 5–19), (p = 0.001)]. The ADA levels in
pleural fluid were similar in the HIV positive and HIV neg-
ative patients, and we found no significant correlation
between ADA values and CD4 cell counts (data not
shown).
QuantiFERON® TB Gold In-Tube results
The absolute concentrations of IFN-γ in blood and pleural
fluid for the 'confirmed TB', 'probable TB' and 'non-TB'
cases are as given in Table 2. There were significant differ-
ences between the three study groups in TB IFN-γ
responses both in blood (p < 0.001) and pleural fluid (p
= 0.022) as well as in PHA (positive control) IFN-γ
responses in blood (p = 0.046) and Nil IFN-γ responses (p
= 0.024) in pleural fluid. In blood, the strongest TB IFN-γ
responses were found in the 'probable TB' group, but both
TB groups had higher values above the cutoff of the QFT-
TB assay compared to the 'non-TB' patients, (p < 0.01). Nil
responses in blood were low and comparable in all
groups, well below the upper cutoff for valid test of 8 IU/
ml. The PHA IFN-γ responses were generally low in both
TB groups as compared to the 'non-TB' cases and for the
'probable TB' group the difference was statistically signifi-
cant (p = 0.02). For the whole group of patients PHA IFN-
γ responses in blood correlated with blood CD4 cell count
(r = 0.600, p = 0.028).
The IFN-γ responses in pleural fluid are given as IU per 1
× 106 mononuclear cells in order to standardise the
results. The TB specific IFN-γ responses were stronger both
for the 'confirmed TB' (p = 0.05) and for the 'probable TB'
(p = 0.008) groups as compared to the 'non-TB' group in
this compartment. Also the concentrations of IFN-γ in the
negative control samples were significantly higher in both
TB groups than that found in the 'non-TB group' (p
<0.05). Still, the Nil values were lower than those meas-
ured in the TB antigen samples, and for the 'probable TB'
group this was statistically significant (p = 0.003). High
IFN-γ Nil levels in the 'non-TB' group, were only found in
the two HIV positive patients (4.2 and 8.8 IU/1 × 106
PFMCs) and not in the HIV negative malignancy patients
(0.14–0.65 IU/1 × 106 PFMCs). The various IFN-γ
responses in pleural fluid did not correlate to either ADA
or CD4 cell count.
By using the definition of cutoff values and valid tests as
described, 16 (50%) of the QFT-TB results were conclusive
in pleural fluid compared to 23 (79%) in blood. This per-
centage varied according to HIV status (Table 3) and
whether TB was confirmed by culture (Table 4). In the
'confirmed TB' group 8/12 (67%) cases were conclusive in
blood and 3/11 (27%) cases were conclusive in pleural
fluid. The corresponding numbers for the 'probable TB'
group were 10/12 (83%) and 10/16 (63%). There was
agreement between the two compartments in 15 of the
cases. Seven patients showed positive QFT-TB test in
blood, whereas the results were indeterminate in pleural
fluid. In contrast, in two HIV positive 'confirmed TB'
patients the QFT-TB was positive in pleural fluid, whereas
the results in blood were indeterminate and negative,
Table 2: Interferon-gamma (IFN-γ) responses (TB antigen, PHA and nil) in blood (n = 29) and pleural fluid (n = 32)a)
TB antigens Positive control (PHA) Negative control (nil)
Blood (IU/ml)
Confirmed TB pleuritis (n = 12) 1.20 (0.11–11.80)be 1.24 (0.11–15.00) 0.22 (0.05–2.06)
Probable TB pleuritis (n = 12) 3.97 (0.32–11.05)be 0.50 (0.10–4.00)c 0.22 (0.07–1.62)
Non-TB pleuritis (n = 5) 0.13 (0.08–0.31) 15.00 (1.23–15.00) 0.10 (0.07–0.18)
Pleural fluid (IU/1 × 106 PFMCs)
Confirmed TB pleuritis (n = 16) 14.40 (2.15–169.00) 11.45 (1.85–81.20) 8.90 (2.10–55.60)d
Probable TB pleuritis (n = 11) 19.18 (1.31–143.90)be 16.60 (0.95–118.00) 15.23 (0.87–103.00)b
Non-TB pleuritis (n = 5) 1.10 (0.13–7.30) 4.60 (2.20–9.00) 0.70 (0.14–8.80)
Data are presented as medians. The ranges are listed in brackets. PFMC = pleural fluid mononuclear cells.
a) It was not possible to obtain blood from five patients and pleural fluid from two patients.
b) p < 0.01, c) p = 0.02, d)p = 0.03 compared with the 'non-TB group'. e) p < 0.01 compared with negative control.Page 4 of 8
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due to low PHA responses, whereas indeterminate results
in pleural fluid were caused by high negative control sam-
ples. The number of cases with indeterminate QFT-TB
results increased in blood as the CD4 cell count decreased
below 100 cells/microL (Table 3). In contrast, there
seemed to be more conclusive results in pleural fluid with
low CD4 cell count.
In pleural fluid 12 (44%) of the 27 TB cases tested by the
QFT-TB assay were positive, 14 (52%) gave indeterminate
results whereas one was negative (3.7%) (Table 4). In
blood 17 (71%) of the 24 tested TB cases were positive, six
indeterminate (25%) and one negative (4.2%). Two of
the 'non-TB' cases, both HIV positive, had indeterminate
QFT-TB tests in pleural fluid, whereas all had conclusive
negative results in blood. This gave sensitivities of the
QFT-TB test in pleural fluid of 27% and 56% in the 'con-
firmed TB' cases and 'probable TB' cases respectively,
whereas the corresponding sensitivities in blood were
58% and 83%. However, if the indeterminate results were
excluded from the analyses, the sensitivities of QFT-TB
were 94% and 87% in blood and 100% and 90% in pleu-
ral fluid in the 'confirmed TB' and 'probable TB' cases,
respectively.
Discussion
Tuberculous pleuritis is an AIDS defining illness and a
common opportunistic infection in endemic areas like
South Africa. Kaposi sarcoma and bacterial infections
could also cause pleural effusion in HIV infected patients,
making diagnosis difficult [28]. The majority of the TB
patients in this study had low CD4 cell counts, reflecting
the serious implication of this disease in sub-Saharan
Africa. Further, we confirm that low CD4 cell count could
also be found in HIV negative TB pleuritis patients [29].
This is to our knowledge the first study evaluating the 2nd
generation QFT-TB assay in the diagnosis of pleural TB,
testing in parallel blood and pleural fluid from HIV
infected patients. IFN-γ based assays have been studied in
the diagnosis of extrapulmonary TB [16,19,21], but few
studies have included HIV positive patients [18,20,30]. In
patients with pleural TB, the tests have predominantly
been performed on blood samples and not evaluated for
directly use on pleural fluid specimens [22,23]. Finally,
there has been inadequate evidence on the validity of IFN-
γ assays in immunocompromised individuals, especially
in countries where TB is endemic [31].
In this group of South African TB pleuritis patients with
predominantly advanced HIV disease the overall sensitiv-
ity of the QFT-TB test in blood was 71% compared to only
44% in pleural fluid. The sensitivity in blood is compara-
ble to that found in other studies of extrapulmonary TB in
HIV negative patients, reporting sensitivities of IGRA-tests
between 70–90% [16,19,21]. In a study of South African
children with TB, the sensitivity of the ELISPOT assay was
reduced from 83% in HIV negative to 73% in HIV positive
children [20]. Our QFT-TB results are slightly superior to
that reported by Sohn et al using the 1st generation QFT-
TB test based on PPD in 28 suspected HIV negative TB
pleuritis patients [22]. Assuming lower sensitivities if
immunocompromised patients were included in their
study, our data suggests that the 2nd generation QFT-TB is
more sensitive not only in blood [17], but also in pleural
fluid than the original QFT-TB test. In comparison, only
40% of our patients were confirmed TB by culture, which
is comparable to other studies of HIV negative TB pleuritis
patients [3]. Although the 'non-TB' control group was too
small to give a reliable estimate of specificity, no false pos-
itive QFT-TB results were found in any of the compart-
ments indicating that the QFT-TB seems to be a
reasonable good 'rule-in' test.
In blood we found overall 25% indeterminate results in
the TB patients due to weak mitogen PHA IFN-γ
responses. The percentage of indeterminate results in
blood increased as the CD4 cell count decreased, most
likely caused by T cell anergy, typically seen in advanced
HIV infection [32]. However, several patients had CD4
cell counts in the range of 50–100 cells/μL, but still posi-
tive QFT-TB tests both in blood and pleural fluid. In con-
trast, non-conclusive results could also be obtained in
blood from HIV patients with rather high CD4 cell count,
indicating that also the quality of the individual's immu-
nity is a prerequisite for a conclusive test. Studies of
patients on immunosuppressive therapy [19] and with
Table 3: Conclusive results of the QuantiFERON®-TB Gold assay in peripheral blood (n = 29) and pleural fluid (n = 32) stratified by HIV 
status and CD4 cell count.
HIV positive
Total CD4 > 200 CD4 100–200 CD4 < 100 HIV negative
Peripheral blood 15/21 (71%) 2/2 (100%) 5/6 (83%) 7/11 (64%) 8/8 (100%)
Pleural fluid 10/24 (48%) 0/2 (0%) 2/6 (33%) 7/13 (54%) 6/8 (75%)
The nominator varies according to the number of patients tested by the assay in each group.Page 5 of 8
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indeterminate results. These data point to the fact that
inconclusive results from blood are more common in
immunocompromised patients.
For the patients with 'confirmed TB' the sensitivity of QFT-
TB was only 58% in blood and 27% in pleural fluid,
whereas corresponding sensitivities were 83% and 56%
for the culture negative 'probable TB' patients. It is
reported that positive culture are more common in
advanced HIV patients compared to HIV negative TB pleu-
ritis patients [33], possibly explained by spread of M.
tuberculosis from the lungs into the pleural space increas-
ing the mycobacteria concentration. Since we found a cor-
relation between CD4 cell count and PHA responses in
blood, the trend towards lower CD4 cell counts in the
'confirmed TB' group could explain the larger number of
indeterminate results due to low PHA responses in this
group.
In contrast, in pleural fluid we found no correlation
between blood CD4 cell count and PHA IFN-γ responses,
and in this compartment TB and PHA responses were gen-
erally strong. Rather, indeterminate results were due to
high levels of IFN-γ measured in the negative control sam-
ples. Patients with pleural TB co-infected with HIV have a
higher rate of pleural inflammation than that observed in
HIV negative persons [10], which could explain the high
IFN-γ responses in the negative control samples. Back-
ground responses were not correlated to blood CD4 cell
count, but were especially seen in HIV patients with CD4
cell counts at the upper range for this cohort. Even the two
HIV patients in the 'non-TB' group had high IFN-γ concen-
trations in the negative control samples, yet at a lower
level than seen in the TB groups. This supports previous
studies reporting high levels of chronic immune activa-
tion and compartmentalisation of immune cells in lym-
phoid tissue and lungs of HIV patients from early disease
[34,35]. A marked increase in activated memory T cells
has also been found in HIV negative patients with tuber-
culous pleurisy [36]. In contrast, the HIV negative 'non-
TB' patients with malignancy had all very low IFN-γ back-
ground levels, as earlier reported [37].
A recent meta-analysis concludes that IFN-γ is a sensitive
and specific test for the diagnosis of tuberculous pleurisy
[38]. However, in HIV endemic areas one should be aware
of the problem with high background signals in HIV
patients causing difficulties interpreting the results. Fur-
ther, there seems to be a compartmentalisation of TB spe-
cific and unspecific immune responses in pleural fluid
and blood, especially in HIV positive patients, as reported
in our study. Thus, the cutoff value for a positive QFT-TB
test could be different in pleural fluid where immune
responses seem to be at a higher 'set-point' than in blood.
We also observed that there was a large variation in con-
centration of cells as well as strength of responses between
the various patients.
In the TB groups the TB antigen IFN-γ responses were sig-
nificantly higher than the IFN-γ responses in the respec-
tive negative control samples, indicating that the actual TB
antigen value was above background signals when a con-
clusive result was given. For two of the patients with a pos-
itive test in pleural fluid, QFT-TB in blood was not
conclusive. Advanced HIV patients suffer from various
opportunistic pulmonary infections making precise diag-
nosis difficult. Thus, testing QFN-TB in pleural fluid could
at certain occasions help diagnosing culture negative TB
pleuritis in the HIV positive population and contribute to
decision making in the clinical setting. Still, further stud-
ies are needed to determine optimal culture conditions
and appropriate cutoff values as well as the usefulness and
cost benefit of the QFT-TB test before it could be recom-
mended for use as a diagnostic test of TB pleuritis in a TB/
HIV endemic resource-limited setting.
Table 4: Results of the QuantiFERON®-TB Gold assay in peripheral blood (n = 29) and pleural fluid (n = 32)
Total TB Confirmed TB Probable TB Non-TB
QFT-TB positive test
Peripheral blood 17/24 (71%) 7/12 (58%) 10/12 (83%) 0/5 (0%)
Pleural fluid 12/27 (44%) 3/11 (27%) 9/16 (56%) 0/5 (0%)
QFT-TB negative test
Peripheral blood 1/24 (4.2%) 1/12 (8.3%) 0/12 (0%) 5/5 (100%)
Pleural fluid 1/27 (3.7%) 0/11 (0%) 1/16 (6.3%) 3/5 (60%)
QFT-TB indeterminate test
Peripheral blood 6/24 (25%) 4/12 (33%) 2/12 (17%) 0/5 (0%)
Pleural fluid 14/27 (52%) 8/11 (71%) 6/16 (38%) 2/5 (40%)
The nominator varies according to the number of patients tested by the assay in each group. It was not possible to obtain blood from five patients 
and pleural fluid from two patients.Page 6 of 8
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patients with pleural effusion with QFT-TB could be use-
ful and improve management of patients as culture results
take time to obtain and pleural fluid sampling not always
possible to perform. We have shown that despite the risk
of indeterminate results in HIV patients with low CD4 cell
counts, testing of blood offers a better sensitivity than in
pleural fluid with a high positive predictive value. In sup-
port of this, Connell et al. have reported two perinatal TB
cases where culture was positive only after six weeks, but
QFT-TB results were available within 48 hours resulting in
adequate and successful treatment for the patients [39].
Further, in our study five TB patients had ADA in the range
of 30–45 U/L. Some clinicians use ADA cutoff values at 45
U/L to exclude false positive tests [7]. Our data demon-
strate that a positive OFT-TB could contribute to the TB
diagnosis in patients with negative culture and ADA val-
ues close to cutoff values.
Conclusion
The commercial QFT-TB test in blood may prove to be
useful in the diagnosis of TB pleuritis in the HIV positive
population in order to urge initiation of TB therapy.
Although the QFT-TB test in pleural fluid in certain cases
could contribute to the TB diagnosis in HIV patients with
low CD4 cell counts, our data do not support the routine
use of this test in pleural fluid at this stage. Thus, further
and larger studies are needed to determine appropriate
cutoff values as well as the usefulness and cost benefit of
this test before it could be recommended for use as a diag-
nostic tool in a TB/HIV endemic resource-limited setting.
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